Mirantus

Who owns Mirantus?

Mirantus is currently owned by Revent through Revent Fund II (2025 vintage), since 2025.

Hand-verified · updated 2026-07-03

About Mirantus

Mirantus Health is a Berlin-based health technology company whose "mira" software platform brings ophthalmological screening into opticians' stores across German-speaking Europe. Through the platform, opticians capture retinal images, intraocular pressure measurements, slit-lamp images, refraction data and visual acuity tests on site, then forward the data digitally to ophthalmologists who return an evaluation report within 24 to 48 hours rather than after months of waiting. The company also runs mobile screening units, branded "Augenmobile," that carry these services to rural communities and nursing homes. It addresses the growing strain on eye care in Europe, where a retiring specialist workforce meets rising demand from an ageing population. According to the company, "mira" was already active at more than 200 locations at the time of its 2025 funding round.

Ownership journey

Mirantus Health was founded in Berlin in 2022 by Dominik Pederzani and Dr. med. Claus Gruber to widen access to eye screening through opticians and mobile units. In November 2025 the company closed a EUR 5.5 million seed round in which Revent invested through Revent Fund II, alongside other backers and angel investors. Revent is a minority venture backer rather than a controlling owner, and it remains an active investor. No exit or secondary transaction has been recorded.

Under PE ownership

The November 2025 seed capital was earmarked for expanding the digital platform and accelerating its rollout across the DACH region. Under the investment, Mirantus has set a target of extending "mira" from more than 200 locations to over 1,000 across Germany, Austria and Switzerland by 2027. The platform's model, delivering an ophthalmologist-reviewed report within 24 to 48 hours, positions the company to scale point-of-care screening as demand for eye care outpaces specialist capacity. As the round is recent, most operating milestones under Revent's backing lie ahead rather than realised.